secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0000950170-24-038055
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics reports FY2023 net loss of $64.7M; Phase 2/3 trial paused, topline expected summer 2024
--------------------------------------------------------------------------------

- Net loss FY2023 $64.7M vs $41.0M prior year; Q4 net loss $16.9M vs $11.8M.
- Cash, equivalents and investments $134.5M at Dec 31, 2023.
- Phase 3 enrollment in epetraborole TR-MAC trial paused voluntarily Feb 2024 due to potentially lower efficacy; Phase 2 topline results expected summer 2024.
- Plan to discuss Phase 2/3 data with FDA; no safety concerns prompted pause.
- Executed license from UGA for Chagas disease candidate AN2-502998; Gates Foundation grant for TB/malaria.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000095017024038055/0000950170-24-038055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000095017024038055/antx-20240328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-038055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer